- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01062750
Liver Regeneration Therapy by Intrahepatic Arterial Administration of Autologous Adipose Tissue Derived Stromal Cells
September 4, 2015 updated by: Shuichi Kaneko, Kanazawa University
Mesenchymal stem cells have capability to differentiate into hepatocyte and will be useful for liver regeneration.
Adipose tissue is relatively enriched with mesenchymal stem cell compared to bone marrow tissue.
In this trial, eligible liver cirrhosis patients will receive autologous adipose tissue derived stromal cells through intrahepatic arterial catheterization.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The population of the liver cirrhosis patients is enormous in Japan and the only radical treatment for them is liver transplantation: however, the number of giving donor is extremely limited.
Mesenchymal stem cells have been capable to differentiate into mesodermal-lineage cells as well as endodermal-lineage cells such as hepatocytes.
They reside in the mesenchymal tissues such as bone marrows as well as adipose tissues.
The latter tissues are relatively enriched with mesenchymal stem cells compared to bone marrow cells.
In this study, the cirrhotic patients will undergo intrahepatic arterial administration of autologous adipose tissue derived stromal cells through catheter.
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ishikawa
-
Kanazawa, Ishikawa, Japan, 920-8641
- Kanazawa University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Criteria defined in the implementation protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: adipose tissue derived stromal cells
|
single administration of autologous adipose tissue derived stroma cells via intrahepatic arterial catheterization
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
all cause harmful events
Time Frame: one month
|
one month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Shuichi Kaneko, M.D., Kanazawa University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2012
Primary Completion (Actual)
February 1, 2015
Study Completion (Actual)
May 1, 2015
Study Registration Dates
First Submitted
February 3, 2010
First Submitted That Met QC Criteria
February 3, 2010
First Posted (Estimate)
February 4, 2010
Study Record Updates
Last Update Posted (Estimate)
September 7, 2015
Last Update Submitted That Met QC Criteria
September 4, 2015
Last Verified
September 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1132
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cirrhosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
-
The Cleveland ClinicRecruitingCirrhosis, LiverUnited States
-
University of PittsburghNational Institute on Drug Abuse (NIDA)CompletedCirrhosis, LiverUnited States
-
Beth Israel Deaconess Medical CenterAmerican Association for the Study of Liver Diseases FoundationCompleted
-
Asian Institute of Gastroenterology, IndiaCompletedCirrhosis, LiverIndia
-
Sherief Abd-ElsalamUnknown
-
Fundació Institut de Recerca de l'Hospital de la...Spanish Clinical Research Network - SCReNWithdrawn
Clinical Trials on adipose tissue derived stromal cells dosage
-
Kanazawa UniversityUnknownIschemic Heart FailureJapan
-
Dr. Himanshu Bansal FoundationCompleted
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Dhaka Medical CollegeCompletedOsteoarthritis KneesBangladesh
-
Mayo ClinicRecruitingKidney TransplantUnited States
-
Instituto de Investigación Sanitaria de la Fundación...Hospital General Universitario Gregorio Marañon; Clinica Universidad de Navarra... and other collaboratorsSuspended
-
Kanazawa UniversityTerminatedLiver CirrhosisJapan
-
Mayo ClinicState of Minnesota Regenerative Medicine MinnesotaActive, not recruitingAmyotrophic Lateral Sclerosis | ALSUnited States
-
Rigshospitalet, DenmarkActive, not recruitingMesenchymal Stem Cells | Xerostomia | Salivary Gland Diseases | Oropharynx Cancer | Hyposalivation | Dry Mouth | Mesenchymal Stromal Cells | Xerostomia Due to Radiotherapy | Stem CellsDenmark
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingMesenchymal Stromal Cells | Lyell Syndrome | Overlap Syndrome | Toxic Epidermal Necrolysis | Epidermal Necrolysis | Adipose Derived Stromal Cells
-
Samuel VilchezNational Autonomous University of Nicaragua; Ministerio de Salud de Nicaragua; GID BIOCompletedChronic Renal Failure of Unknown CauseNicaragua